RAGE gene polymorphisms in patients with multiple sclerosis

Zoltán Tiszlavicz, Zsofia Gyulai, Krisztina Bencsik, Zoltán Szolnoki, Ágnes Katalin Kocsis, Ferenc Somogyvári, László Vécsei, Yvette Mándi

Research output: Article

11 Citations (Scopus)


The pathogenesis of multiple sclerosis (MS), a devastating neuroinflammatory disorder of the central nervous system, has been presumed to involve the possible importance of the receptor for advanced glycation end products (RAGE). The aim of this study was to investigate the relevance of the genetic polymorphisms of RAGE in MS patients. A total of 168 patients with MS were enrolled; 136 healthy blood donors served as controls. The-374 T/A,-479 T/C, and the G82S polymorphisms of RAGE were determined by restriction fragment length polymorphism (RFLP). There was a significant difference in RAGE-374 T/A genotype distribution between the controls and the MS patients. The AA homozygote variants were detected in 8% of the patients with MS, as compared with 19% of healthy controls (OR=2.75; 95% CI=1.319-5.733, p=0.007). No differences were observed between the MS patients and the controls, concerning the frequencies of the-479 T/C and G82S genotypes of the RAGE. Our results revealed an association between the-374 T/A polymorphism of the RAGE promoter and MS. The genetic variant-374 AA (which has previously been shown to exert significant effects on transcriptional activity) can be considered a preventive factor as regards the occurrence of MS. Our findings support the view that RAGE plays a role in the development of MS.

Original languageEnglish
Pages (from-to)360-365
Number of pages6
JournalJournal of Molecular Neuroscience
Issue number3
Publication statusPublished - nov. 1 2009

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'RAGE gene polymorphisms in patients with multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this